Online Only Articles

Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

Stanford University School of Medicine, CA, USA
ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
Medical University of Lodz, Poland
Wilmot Cancer Institute, University of Rochester Cancer Center, NY, USA
Tom Baker Cancer Centre, University of Calgary, Canada
Rabin Medical Center, Beilinson Campus, Petah Tikvah, Israel;Sackler Faculty of Medicine, University, Tel Aviv, Israel
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA
University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA
Vol. 103 No. 6 (2018): June, 2018 https://doi.org/10.3324/haematol.2017.175380